巨子 ICON - 財經股票資訊及專家分析
快訊
資訊
    虛擬市場
    搜尋 股票/指數/編號

    快訊

    資訊

    Windtree Therapeutics

    WINT
    0.377
    0.000
    0.00%
    最少15分鐘延遲,股票資訊由第三方資訊供應商提供
    ・Windtree Therapeutics - 延遲價格・最後更新於 15/08 23:18
    最高位
    --
    最低位
    --
    開市價
    --
    前收市價
    0.377
    成交量(千)
    --
    成交額(百萬)
    --
    買入
    --
    賣出
    0.420
    每手股數
    --
    市值(百萬)
    11.53
    市盈率
    --
    息率
    --
    差價
    --
    52週高低
    2.370 - 0.350
    所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

    企業資料

    公司名稱
    Windtree Therapeutics
    證券代碼
    WINT.US
    所屬板塊
    Biotechnology
    公司業務
    Windtree Therapeutics Inc is a development-stage biotechnology company focused on developing KL4 surfactant therapies for respiratory diseases. Its technology platform includes synthetic, peptide-containing surfactant and novel drug delivery technologies that deliver aerosolized KL4 surfactants without invasive procedures. Its development program utilizing its proprietary technology platform is AEROSURF which is being developed for the treatment of respiratory distress syndrome in premature infants. It operates in the business segment of research and development of products focused on surfactant therapies for respiratory disorders and diseases, and the manufacture and commercial sales of approved products.
    發行量
    28469274
    公司總部
    2600 Kelly Road, Suite 100
    公司網址
    https://www.windtreetx.com
    公司電郵
    ir@discoverylabs.com
    公司電話
    +1 215 488-9300
    暫無內容

    關於

    Windtree Therapeutics(WINT.US)所屬的行業板塊為Biotechnology。
    Windtree Therapeutics Inc is a development-stage biotechnology company focused on developing KL4 surfactant therapies for respiratory diseases. Its technology platform includes synthetic, peptide-containing surfactant and novel drug delivery technologies that deliver aerosolized KL4 surfactants without invasive procedures. Its development program utilizing its proprietary technology platform is AEROSURF which is being developed for the treatment of respiratory distress syndrome in premature infants. It operates in the business segment of research and development of products focused on surfactant therapies for respiratory disorders and diseases, and the manufacture and commercial sales of approved products.
    詳細公司背景可參考: https://www.windtreetx.com